JP2022513797A5 - - Google Patents

Info

Publication number
JP2022513797A5
JP2022513797A5 JP2021533528A JP2021533528A JP2022513797A5 JP 2022513797 A5 JP2022513797 A5 JP 2022513797A5 JP 2021533528 A JP2021533528 A JP 2021533528A JP 2021533528 A JP2021533528 A JP 2021533528A JP 2022513797 A5 JP2022513797 A5 JP 2022513797A5
Authority
JP
Japan
Prior art keywords
orf1
nucleic acid
acid sequence
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021533528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065995 external-priority patent/WO2020123816A2/en
Publication of JP2022513797A publication Critical patent/JP2022513797A/ja
Publication of JP2022513797A5 publication Critical patent/JP2022513797A5/ja
Priority to JP2024075373A priority Critical patent/JP2024099834A/ja
Withdrawn legal-status Critical Current

Links

JP2021533528A 2018-12-12 2019-12-12 アネロソーム及び使用の方法 Withdrawn JP2022513797A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075373A JP2024099834A (ja) 2018-12-12 2024-05-07 アネロソーム及び使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862778841P 2018-12-12 2018-12-12
US201862778866P 2018-12-12 2018-12-12
US62/778,866 2018-12-12
US62/778,841 2018-12-12
PCT/US2019/065995 WO2020123816A2 (en) 2018-12-12 2019-12-12 Anellosomes and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075373A Division JP2024099834A (ja) 2018-12-12 2024-05-07 アネロソーム及び使用の方法

Publications (2)

Publication Number Publication Date
JP2022513797A JP2022513797A (ja) 2022-02-09
JP2022513797A5 true JP2022513797A5 (enExample) 2022-12-20

Family

ID=69165586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533528A Withdrawn JP2022513797A (ja) 2018-12-12 2019-12-12 アネロソーム及び使用の方法
JP2024075373A Pending JP2024099834A (ja) 2018-12-12 2024-05-07 アネロソーム及び使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075373A Pending JP2024099834A (ja) 2018-12-12 2024-05-07 アネロソーム及び使用の方法

Country Status (11)

Country Link
US (1) US12637693B2 (enExample)
EP (1) EP3894570A2 (enExample)
JP (2) JP2022513797A (enExample)
KR (1) KR20210131310A (enExample)
CN (1) CN113631716A (enExample)
AU (1) AU2019397058A1 (enExample)
BR (1) BR112021011124A2 (enExample)
CA (1) CA3121528A1 (enExample)
IL (1) IL283782A (enExample)
MX (1) MX2021006977A (enExample)
WO (1) WO2020123816A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112019022539A2 (pt) 2017-04-28 2020-06-16 Agrospheres, Inc. Composições e métodos para o encapsulamento e entrega escalonável de agorquímicos
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
AU2021288320A1 (en) * 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
CA3206361A1 (en) * 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
EP4337235A4 (en) * 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US5773258A (en) 1995-08-25 1998-06-30 Roche Molecular Systems, Inc. Nucleic acid amplification using a reversibly inactivated thermostable enzyme
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1998013501A2 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
DE10120797B4 (de) 2001-04-27 2005-12-22 Genovoxx Gmbh Verfahren zur Analyse von Nukleinsäureketten
US20120148585A1 (en) 2001-05-01 2012-06-14 Andrew Saxon Fusion molecules and methods for treatment of immune diseases
DE10239504A1 (de) 2001-08-29 2003-04-24 Genovoxx Gmbh Verfahren zur Analyse von Nukleinsäurekettensequenzen und der Genexpression
WO2003031947A2 (de) 2001-10-04 2003-04-17 Genovoxx Gmbh Gerät zur sequenzierung von nukleinsäuremolekülen
DE10149786B4 (de) 2001-10-09 2013-04-25 Dmitry Cherkasov Oberfläche für Untersuchungen aus Populationen von Einzelmolekülen
DE10214395A1 (de) 2002-03-30 2003-10-23 Dmitri Tcherkassov Verfahren zur Analyse von Einzelnukleotidpolymorphismen
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7407744B2 (en) 2003-07-25 2008-08-05 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
DE10356837A1 (de) 2003-12-05 2005-06-30 Dmitry Cherkasov Modifizierte Nukleotide und Nukleoside
DE102004009704A1 (de) 2004-02-27 2005-09-15 Dmitry Cherkasov Makromolekulare Nukleotidverbindungen und Methoden zu deren Anwendung
DE102004025745A1 (de) 2004-05-26 2005-12-15 Cherkasov, Dmitry Oberfläche für die Analysen an einzelnen Molekülen
DE102004025695A1 (de) 2004-05-26 2006-02-23 Dmitry Cherkasov Verfahren und Oberfläche zur parallelen Sequenzierung von Nukleinsäureketten
DE102004025744A1 (de) 2004-05-26 2005-12-29 Dmitry Cherkasov Oberfläche für die Analysen an einzelnen Nukleinsäuremolekülen
DE102004025696A1 (de) 2004-05-26 2006-02-23 Dmitry Cherkasov Verfahren, Oberfläche und Substrate zu hochparallelen Analysen von Nukleinsäureketten
DE102004025694A1 (de) 2004-05-26 2006-02-23 Dmitry Cherkasov Verfahren und Oberfläche zu hochparallelen Analysen von Nukleinsäureketten
DE102004025746A1 (de) 2004-05-26 2005-12-15 Dmitry Cherkasov Verfahren, Oberfläche und Substrate zur hochparallelen Sequenzierung von Nukleinsäureketten
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
DE102006012317A1 (de) 2005-03-17 2007-01-18 Cherkasov, Dmitry, Dr. Makromolekulare Nukleotidverbindungen und Methoden zu deren Anwendung
WO2006133316A2 (en) 2005-06-06 2006-12-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Tumor suppressor gene caliban
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP1992691A1 (en) 2007-05-16 2008-11-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts New TTV sequences for diagnosis, prevention and treatment of childhood leukaemia
GB2452535A (en) 2007-09-07 2009-03-11 Ericsson Telefon Ab L M Optimising packet switched networks
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
WO2010099510A2 (en) 2009-02-27 2010-09-02 The Administrators Of The Tulane Educational Fund Amino acid-based compounds, their methods of use, and methods of screening
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
WO2011017162A2 (en) 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
US9249192B2 (en) * 2009-08-21 2016-02-02 Virginia Tech Intellectual Properties, Inc. Infectious genomic DNA clone and serological profile of Torque teno sus virus 1 and 2
US9676828B2 (en) 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US20110318363A1 (en) 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP2016523076A (ja) 2013-06-14 2016-08-08 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 癌の将来の発生についての早期マーカーならびに癌の治療および予防のための標的としてのＴＴＶ ｍｉＲＮＡ配列
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
CN105899658B (zh) * 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3359663A4 (en) 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
BR112019011138A2 (pt) 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
KR20200067195A (ko) 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
US20230048858A1 (en) * 2018-12-12 2023-02-16 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering secreted therapeutic modalities
EP3894567A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering intracellular therapeutic modalities
KR20230036109A (ko) 2020-06-12 2023-03-14 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 바큘로바이러스 발현 시스템
AU2021288320A1 (en) 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
KR20230041686A (ko) 2020-06-17 2023-03-24 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
US20240000914A1 (en) 2020-10-29 2024-01-04 Flagship Pioneering Innovations V, Inc. Chicken anemia virus (cav)-based vectors
CA3206361A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
WO2022170195A1 (en) 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
EP4337235A4 (en) 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE
MX2024004492A (es) 2021-10-12 2024-05-31 Flagship Pioneering Innovations V Inc Composiciones y metodos de anellovector novedosos.
TW202334423A (zh) 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒
US20240327867A1 (en) 2023-03-15 2024-10-03 Flagship Pioneering Innovations V, Inc. Anellovirus constructs comprising recombination sites and cross-packaging of anellovector particles and genetic elements
US20240415978A1 (en) 2023-06-14 2024-12-19 Flagship Pioneering Innovations V, Inc. Anellovectors for delivery of effectors to the central nervous system

Similar Documents

Publication Publication Date Title
JP2022512395A5 (enExample)
JP2022514501A5 (enExample)
JP2020524993A5 (enExample)
KR101817482B1 (ko) 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
JP2022513459A5 (enExample)
KR102805002B1 (ko) Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
TW201945388A (zh) 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
KR20210131309A (ko) 분비형 치료 양식을 운반하기 위한 아넬로좀
KR20210131310A (ko) 아넬로좀 및 사용 방법
KR20210125990A (ko) 단백질 대체 치료 양식을 운반하기 위한 아넬로좀
KR20210131308A (ko) 세포내 치료 양식을 운반하기 위한 아넬로좀
JP2024521894A (ja) ＲＮＡ誘導型ＣａｓΩヌクレアーゼ並びに診断及び治療におけるその使用
EP4696777A1 (en) Cas13 protein, and crispr-cas system and use thereof
KR20250053925A (ko) CRISPR-Cas13 시스템 및 이의 용도
CN110431230A (zh) 慢病毒和非整合型慢病毒作为病毒载体实施crispr治疗
KR20230036110A (ko) 탠덤 아넬로바이러스 구축물
CA2485341A1 (en) Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
KR20010042848A (ko) 인슐린유사 성장인자 ⅱ의 안티센스 올리고뉴클레오타이드서열 및 이를 이용한 세포성장 조절방법
CN102140473B (zh) 抗肿瘤的核酸与多肽及其应用
Su et al. Identification of gene products suppressed by human immunodeficiency virus type 1 infection or gp120 exposure of primary human astrocytes by rapid subtraction hybridization
CN117860902B (zh) 一种前列腺癌分子靶向系统及其构建方法和应用
US20220241426A1 (en) Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
CN114306367B (zh) 一种含有C/EBPα-saRNA的组合物
TW202246510A (zh) 以crispr/slucas9治療第1型肌強直性營養不良之組合物及方法
CA2251818A1 (en) Mammalian genes involved in viral infection and tumor suppression